Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression.

Mardiana S, Solomon BJ, Darcy PK, Beavis PA.

Sci Transl Med. 2019 Jun 5;11(495). pii: eaaw2293. doi: 10.1126/scitranslmed.aaw2293. Review.

PMID:
31167925
2.

Switching on the green light for chimeric antigen receptor T-cell therapy.

Mardiana S, Lai J, House IG, Beavis PA, Darcy PK.

Clin Transl Immunology. 2019 May 5;8(5):e1046. doi: 10.1002/cti2.1046. eCollection 2019. Review.

3.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
4.

Antagonism of IAPs Enhances CAR T-cell Efficacy.

Michie J, Beavis PA, Freeman AJ, Vervoort SJ, Ramsbottom KM, Narasimhan V, Lelliott EJ, Lalaoui N, Ramsay RG, Johnstone RW, Silke J, Darcy PK, Voskoboinik I, Kearney CJ, Oliaro J.

Cancer Immunol Res. 2019 Feb;7(2):183-192. doi: 10.1158/2326-6066.CIR-18-0428. Epub 2019 Jan 16.

PMID:
30651288
5.

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy.

Sek K, Mølck C, Stewart GD, Kats L, Darcy PK, Beavis PA.

Int J Mol Sci. 2018 Dec 2;19(12). pii: E3837. doi: 10.3390/ijms19123837. Review.

6.

Publisher Correction: Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S.

Nat Med. 2018 Dec;24(12):1941. doi: 10.1038/s41591-018-0176-6.

PMID:
30135555
7.

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, Westwood JA, Sandhu S, Raleigh JM, Behren A, Cebon J, Darcy PK, Kershaw MH, McArthur GA, Gyorki DE, Neeson PJ.

Sci Rep. 2018 Jul 24;8(1):11158. doi: 10.1038/s41598-018-28944-3.

8.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.

Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK.

Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17.

PMID:
30018045
9.

CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.

Slaney CY, Wang P, Darcy PK, Kershaw MH.

Cancer Discov. 2018 Aug;8(8):924-934. doi: 10.1158/2159-8290.CD-18-0297. Epub 2018 Jul 16. Review.

PMID:
30012854
10.

IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma.

Van Der Weyden C, Bagot M, Neeson P, Darcy PK, Prince HM.

Expert Opin Investig Drugs. 2018 Aug;27(8):691-697. doi: 10.1080/13543784.2018.1498081. Epub 2018 Jul 17. Review.

PMID:
30001170
11.

Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, Salgado R, Byrne DJ, Teo ZL, Dushyanthen S, Byrne A, Wein L, Luen SJ, Poliness C, Nightingale SS, Skandarajah AS, Gyorki DE, Thornton CM, Beavis PA, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Darcy PK, Speed TP, Mackay LK, Neeson PJ, Loi S.

Nat Med. 2018 Jul;24(7):986-993. doi: 10.1038/s41591-018-0078-7. Epub 2018 Jun 25. Erratum in: Nat Med. 2018 Dec;24(12):1941.

PMID:
29942092
12.

Tumor immune evasion arises through loss of TNF sensitivity.

Kearney CJ, Vervoort SJ, Hogg SJ, Ramsbottom KM, Freeman AJ, Lalaoui N, Pijpers L, Michie J, Brown KK, Knight DA, Sutton V, Beavis PA, Voskoboinik I, Darcy PK, Silke J, Trapani JA, Johnstone RW, Oliaro J.

Sci Immunol. 2018 May 18;3(23). pii: eaar3451. doi: 10.1126/sciimmunol.aar3451.

PMID:
29776993
13.

Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review.

Van Audenaerde JRM, Roeyen G, Darcy PK, Kershaw MH, Peeters M, Smits ELJ.

Pharmacol Ther. 2018 Sep;189:31-44. doi: 10.1016/j.pharmthera.2018.04.003. Epub 2018 Apr 13.

PMID:
29660367
14.

Bi-Allelic Mutations in STXBP2 Reveal a Complementary Role for STXBP1 in Cytotoxic Lymphocyte Killing.

Lopez JA, Noori T, Minson A, Li Jovanoska L, Thia K, Hildebrand MS, Akhlaghi H, Darcy PK, Kershaw MH, Brown NJ, Grigg A, Trapani JA, Voskoboinik I.

Front Immunol. 2018 Mar 15;9:529. doi: 10.3389/fimmu.2018.00529. eCollection 2018.

15.

Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myeloma.

Gherardin NA, Loh L, Admojo L, Davenport AJ, Richardson K, Rogers A, Darcy PK, Jenkins MR, Prince HM, Harrison SJ, Quach H, Fairlie DP, Kedzierska K, McCluskey J, Uldrich AP, Neeson PJ, Ritchie DS, Godfrey DI.

Sci Rep. 2018 Mar 7;8(1):4159. doi: 10.1038/s41598-018-22130-1.

16.

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.

Oliver AJ, Lau PKH, Unsworth AS, Loi S, Darcy PK, Kershaw MH, Slaney CY.

Front Immunol. 2018 Jan 31;9:70. doi: 10.3389/fimmu.2018.00070. eCollection 2018. Review.

17.

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.

Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, Darcy PK, Neeson PJ, Jenkins MR.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2068-E2076. doi: 10.1073/pnas.1716266115. Epub 2018 Feb 12. Erratum in: Proc Natl Acad Sci U S A. 2019 May 28;116(22):11075-11076.

18.

An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy.

Westwood JA, Ellis S, Danne J, Johnson C, Oorschot V, Ramm G, Tscharke DC, Davenport AJ, Whisstock JC, Darcy PK, Kershaw MH, Slaney CY.

Oncotarget. 2017 Dec 14;8(70):115215-115229. doi: 10.18632/oncotarget.23215. eCollection 2017 Dec 29.

19.

Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer.

Teo ZL, Versaci S, Dushyanthen S, Caramia F, Savas P, Mintoff CP, Zethoven M, Virassamy B, Luen SJ, McArthur GA, Phillips WA, Darcy PK, Loi S.

Cancer Res. 2017 Nov 15;77(22):6340-6352. doi: 10.1158/0008-5472.CAN-17-2210. Epub 2017 Sep 25.

20.

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.

Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S.

Nat Commun. 2017 Sep 19;8(1):606. doi: 10.1038/s41467-017-00728-9.

21.

Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.

Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS.

Cancer Immunol Res. 2017 Oct;5(10):871-884. doi: 10.1158/2326-6066.CIR-17-0150. Epub 2017 Aug 28.

22.

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, Lam EYN, Henderson MA, Bell CC, Stolzenburg S, Gilan O, Bloor S, Noori T, Morgens DW, Bassik MC, Neeson PJ, Behren A, Darcy PK, Dawson SJ, Voskoboinik I, Trapani JA, Cebon J, Lehner PJ, Dawson MA.

Nature. 2017 Sep 7;549(7670):101-105. doi: 10.1038/nature23643. Epub 2017 Aug 16.

23.

A Novel Target Antigen for the Treatment of Acute Myeloid Leukemia by CAR T Cells.

Beavis PA, Sek K, Darcy PK.

Mol Ther. 2017 Sep 6;25(9):1997-1998. doi: 10.1016/j.ymthe.2017.07.001. Epub 2017 Jul 14. No abstract available.

24.

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, Seliger B, Marincola FM.

Eur J Cancer. 2017 Aug;81:116-129. doi: 10.1016/j.ejca.2017.01.035. Epub 2017 Jun 15. Review.

PMID:
28623775
25.

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.

Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Perou CM, Visvader JE, Gray DHD, Loi S, Lindeman GJ.

Sci Transl Med. 2017 Jun 7;9(393). pii: eaal4922. doi: 10.1126/scitranslmed.aal4922.

26.

A novel combination strategy for effectively targeting cancer stem-like cells.

Beavis PA, Petley EV, Darcy PK.

Immunol Cell Biol. 2017 Aug;95(7):573-574. doi: 10.1038/icb.2017.39. Epub 2017 Jun 6. No abstract available.

PMID:
28529324
27.

Immunotherapy of cancer.

Trapani JA, Darcy PK.

Aust Fam Physician. 2017;46(4):194-199.

28.

HDAC Inhibitor Panobinostat Engages Host Innate Immune Defenses to Promote the Tumoricidal Effects of Trastuzumab in HER2+ Tumors.

Medon M, Vidacs E, Vervoort SJ, Li J, Jenkins MR, Ramsbottom KM, Trapani JA, Smyth MJ, Darcy PK, Atadja PW, Henderson MA, Johnstone RW, Haynes NM.

Cancer Res. 2017 May 15;77(10):2594-2606. doi: 10.1158/0008-5472.CAN-16-2247. Epub 2017 Mar 1.

29.

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1.

Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, Beavis PA, Darcy PK, Martin BP, Spencer A, Traunbauer AK, Sadovnik I, Bauer K, Valent P, Bradner JE, Zuber J, Shortt J, Johnstone RW.

Cell Rep. 2017 Feb 28;18(9):2162-2174. doi: 10.1016/j.celrep.2017.02.011.

30.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

31.

A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK.

Cancer Res. 2017 Mar 15;77(6):1296-1309. doi: 10.1158/0008-5472.CAN-16-1831. Epub 2017 Jan 12.

32.

CAR T-cell therapy of solid tumors.

Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH.

Immunol Cell Biol. 2017 Apr;95(4):356-363. doi: 10.1038/icb.2016.128. Epub 2016 Dec 22. Review.

PMID:
28003642
33.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

34.

Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.

Kearney CJ, Ramsbottom KM, Voskoboinik I, Darcy PK, Oliaro J.

Oncoimmunology. 2016 Jun 27;5(8):e1196308. doi: 10.1080/2162402X.2016.1196308. eCollection 2016 Aug.

35.

Immunosuppressive activities of adenosine in cancer.

Allard B, Beavis PA, Darcy PK, Stagg J.

Curr Opin Pharmacol. 2016 Aug;29:7-16. doi: 10.1016/j.coph.2016.04.001. Epub 2016 May 19. Review.

PMID:
27209048
36.

The double-edged sword of IFN-γ-dependent immune-based therapies.

John LB, Darcy PK.

Immunol Cell Biol. 2016 Jul;94(6):527-8. doi: 10.1038/icb.2016.37. Epub 2016 May 10. No abstract available.

PMID:
27167903
37.

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.

Yong CS, John LB, Devaud C, Prince MH, Johnstone RW, Trapani JA, Darcy PK, Kershaw MH.

Oncotarget. 2016 Jun 7;7(23):34582-98. doi: 10.18632/oncotarget.9149.

38.

The Role of the immunological Synapse Formed by Cytotoxic Lymphocytes in Immunodeficiency and Anti-Tumor immunity.

Kearney CJ, Brennan AJ, Darcy PK, Oliaro J.

Crit Rev Immunol. 2015;35(4):325-47. Review.

PMID:
26757394
39.

Clinical relevance of host immunity in breast cancer: from TILs to the clinic.

Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, Loi S.

Nat Rev Clin Oncol. 2016 Apr;13(4):228-41. doi: 10.1038/nrclinonc.2015.215. Epub 2015 Dec 15. Review.

PMID:
26667975
40.

Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.

Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ, Darcy PK.

Semin Immunol. 2016 Feb;28(1):64-72. doi: 10.1016/j.smim.2015.11.003. Epub 2015 Nov 25. Review.

PMID:
26611350
41.

CAR-T cells are serial killers.

Davenport AJ, Jenkins MR, Ritchie DS, Prince HM, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ.

Oncoimmunology. 2015 Jun 1;4(12):e1053684. eCollection 2015 Dec.

42.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1437.

43.

Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice.

Yong CS, Westwood JA, Schröder J, Papenfuss AT, von Scheidt B, Moeller M, Devaud C, Darcy PK, Kershaw MH.

PLoS One. 2015 Oct 27;10(10):e0140543. doi: 10.1371/journal.pone.0140543. eCollection 2015.

44.

CD73: A potential biomarker for anti-PD-1 therapy.

Beavis PA, Slaney CY, Milenkovski N, Henderson MA, Loi S, Stagg J, Kershaw MH, Darcy PK.

Oncoimmunology. 2015 May 5;4(11):e1046675. eCollection 2015 Nov.

45.

Releasing the Brake on Oncolytic Viral Therapy.

Slaney CY, Darcy PK.

Clin Cancer Res. 2015 Dec 15;21(24):5417-9. doi: 10.1158/1078-0432.CCR-15-1769. Epub 2015 Sep 16.

46.

Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.

Yong CS, Sharkey J, Duscio B, Venville B, Wei WZ, Jones RF, Slaney CY, Mir Arnau G, Papenfuss AT, Schröder J, Darcy PK, Kershaw MH.

PLoS One. 2015 Sep 3;10(9):e0136817. doi: 10.1371/journal.pone.0136817. eCollection 2015.

47.

Relevance of tumor-infiltrating lymphocytes in breast cancer.

Dushyanthen S, Beavis PA, Savas P, Teo ZL, Zhou C, Mansour M, Darcy PK, Loi S.

BMC Med. 2015 Aug 24;13:202. doi: 10.1186/s12916-015-0431-3. Review.

48.

Cross-talk between tumors can affect responses to therapy.

Devaud C, John LB, Westwood JA, Yong CS, Beavis PA, Schwendener RA, Darcy PK, Kershaw MH.

Oncoimmunology. 2015 Jun 17;4(7):e975572. eCollection 2015 Jul.

49.

Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.

Beavis PA, Slaney CY, Kershaw MH, Neeson PJ, Darcy PK.

Immunotherapy. 2015;7(5):499-512. doi: 10.2217/imt.15.16. Review.

PMID:
26065476
50.

Adoptive immunotherapy: a new era for the treatment of cancer.

Darcy PK, Neeson PJ.

Immunotherapy. 2015;7(5):469-71. doi: 10.2217/imt.15.37. No abstract available.

Supplemental Content

Loading ...
Support Center